Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Other Accumulated Expenses (2022 - 2025)

Capricor Therapeutics has reported Other Accumulated Expenses over the past 4 years, most recently at $3.1 million for Q4 2025.

  • Quarterly results put Other Accumulated Expenses at $3.1 million for Q4 2025, up 622.1% from a year ago — trailing twelve months through Dec 2025 was $3.1 million (up 622.1% YoY), and the annual figure for FY2025 was $3.1 million, up 622.1%.
  • Other Accumulated Expenses for Q4 2025 was $3.1 million at Capricor Therapeutics, up from $2.6 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for CAPR hit a ceiling of $3.1 million in Q4 2025 and a floor of $10000.0 in Q4 2023.
  • Median Other Accumulated Expenses over the past 4 years was $89234.0 (2022), compared with a mean of $727720.8.
  • Biggest five-year swings in Other Accumulated Expenses: crashed 88.79% in 2023 and later surged 26121.55% in 2025.
  • Capricor Therapeutics' Other Accumulated Expenses stood at $89234.0 in 2022, then crashed by 88.79% to $10000.0 in 2023, then surged by 4257.12% to $435712.0 in 2024, then skyrocketed by 622.1% to $3.1 million in 2025.
  • The last three reported values for Other Accumulated Expenses were $3.1 million (Q4 2025), $2.6 million (Q3 2025), and $1.4 million (Q2 2025) per Business Quant data.